Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cell.2022.01.012 http://scihub22266oqcxt.onion/10.1016/j.cell.2022.01.012 35216673!8776501!35216673     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\35216673.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Cell 2022 ; 185 (5): 916-938.e58 Nephropedia Template TP {{tp|p=35216673|t=2022. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity |pdf=|usr=}}{{35216673}} gab.com Text A blood atlas of COVID-19 defines hallmarks of disease severity and specificity JO: Cell http://www.kidney.de/pget.php?&tw=1&pmid=35216673 #FOAvip Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete description of specific immune biomarkers. We present here a comprehensive multi-omic blood atlas for patients with varying COVID-19 severity in an integrated comparison with influenza and sepsis patients versus healthy volunteers. We identify immune signatures and correlates of host response. Hallmarks of disease severity involved cells, their inflammatory mediators and networks, including progenitor cells and specific myeloid and lymphocyte subsets, features of the immune repertoire, acute phase response, metabolism, and coagulation. Persisting immune activation involving AP-1/p38MAPK was a specific feature of COVID-19. The plasma proteome enabled sub-phenotyping into patient clusters, predictive of severity and outcome. Systems-based integrative analyses including tensor and matrix decomposition of all modalities revealed feature groupings linked with severity and specificity compared to influenza and sepsis. Our approach and blood atlas will support future drug development, clinical trial design, and personalized medicine approaches for COVID-19. Twit Text FOAVip A blood atlas of COVID-19 defines hallmarks of disease severity and specificity ????Cell http://www.kidney.de/pget.php?&tw=1&pmid=35216673 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=35216673 #FOAvip English Wikipedia <ref>{{Cite pmid|35216673}}</ref> A blood atlas of COVID-19 defines hallmarks of disease severity and specificity #MMPMID35216673 � Cell 2022[Mar]; 185 (5): 916-938.e58 PMID35216673show ga Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete description of specific immune biomarkers. We present here a comprehensive multi-omic blood atlas for patients with varying COVID-19 severity in an integrated comparison with influenza and sepsis patients versus healthy volunteers. We identify immune signatures and correlates of host response. Hallmarks of disease severity involved cells, their inflammatory mediators and networks, including progenitor cells and specific myeloid and lymphocyte subsets, features of the immune repertoire, acute phase response, metabolism, and coagulation. Persisting immune activation involving AP-1/p38MAPK was a specific feature of COVID-19. The plasma proteome enabled sub-phenotyping into patient clusters, predictive of severity and outcome. Systems-based integrative analyses including tensor and matrix decomposition of all modalities revealed feature groupings linked with severity and specificity compared to influenza and sepsis. Our approach and blood atlas will support future drug development, clinical trial design, and personalized medicine approaches for COVID-19. |Adult[MESH] |Biomarkers/*blood[MESH] |Blood Proteins/metabolism[MESH] |COVID-19/blood/*pathology/virology[MESH] |Cell Cycle Proteins/genetics/metabolism[MESH] |Female[MESH] |Humans[MESH] |Influenza, Human/blood/pathology[MESH] |Lymphocytes/immunology/metabolism[MESH] |Machine Learning[MESH] |Male[MESH] |Middle Aged[MESH] |Mitogen-Activated Protein Kinase 14/genetics/metabolism[MESH] |Monocytes/immunology/metabolism[MESH] |Principal Component Analysis[MESH] |Proteome/*analysis[MESH] |SARS-CoV-2/isolation & purification[MESH] |Sepsis/blood/pathology[MESH] |Severity of Illness Index[MESH]A blood atlas of COVID-19 defines hallmarks of disease severity and sp(epmc).pdf DeepDyve Pubget Overpricing